Immunosuppressive potential and side effects of everolimus

American Journal of Transplantation

Volumn 12, Issue 9, 2012, Pages 2563-

  Liefeldt, L ^a   Glander, P ^a   Brakemeier, S ^a   Budde, K ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; HLA ANTIBODY; MYCOPHENOLIC ACID; RAPAMYCIN;

DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; PATIENT ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 84865593658     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04158.x     Document Type: Letter

References (5)

1. Pascual J, Arns W,. Does everolimus increase donor-specific HLA antibodies in kidney transplant recipients? Am J Transplant 2012; 12: 2561-2562.
2. Lebranchu Y, Thierry A, Thervet E, et al,. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the postconcept study. Am J Transplant 2011; 11: 1665-1675.
3. Thierry A, Thervet E, Vuiblet V, et al,. Long-term impact of subclinical inflammation diagnosed by protocol biopsy one year after renal transplantation. Am J Transplant 2011; 11: 2153-2161.
4. Budde K, Becker T, Arns W, et al,. Everolimus-based, calcineurin- inhibitor-free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. Lancet 2011; 377: 837-847.
5. Budde K,. How to use mTOR inhibitors? The search goes on. Am J Transplant 2011; 11: 1551-1552.